A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium
A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.
Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.
A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.
A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis03/01/2012 - 02/28/2019 (PI)
Celgene Corporation
A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of01/06/2016 - 01/05/2019 (Co-PI)
PI:
Robert W. Simms, MDFred Hutchinson Cancer Research Center Scleroderma Res Fdn
Molecular Imaging of Primary Amyloid Cardiomyopathy04/01/2017 - 03/31/2018 (Co-PI)
PI:
Frederick L. Ruberg, MDThe Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-02
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.
Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.
Showing 10 of 14 results.
Show All Results
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma03/01/2010 - 03/09/2013 (PI)
Onyx Pharmaceuticals, Inc.
A MulticenterPhase II Trial of Velcade, Melphalan, and Dexamethasone (V-MD) in Patients with AL Amyloidosis or LCDD11/10/2008 - 11/09/2010 (PI)
Millennium Pharmaceuticals, Inc.
An Open Label, Phase 1/2 Study of Velcade (bortezomib) for Injection in Subjects with Light Chain Amyloidosis05/09/2005 - 08/31/2010 (PI)
Johnson & Johnson
Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell02/13/2008 - 02/12/2010 (PI)
Millennium Pharmaceuticals, Inc.
54767414AMY300111/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC
Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center
DARA/JANSSEN PI Initiated03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC
NEOD001-CL00209/24/2015 - 09/30/2018 (PI)
Prothena Therapeutics Limited
PRONTO - Protocol NEOD001-20105/13/2016 - 05/31/2018 (PI)
Prothena Therapeutics Limited
Secondary Analysis of Amyloid Repository Data09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited